APA (7th ed.) Citation

Proetel, U., Müller, M. C., Hanfstein, B., Kalmanti, L., Schreiber, A., Hofmann, W., . . . Saußele, S. (2014). Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: A subanalysis of the randomized CML-Study IV. Annals of hematology, 93(7), .

Chicago Style (17th ed.) Citation

Proetel, Ulrike, Martin Christian Müller, Benjamin Hanfstein, Lida Kalmanti, Annette Schreiber, Wolf-Karsten Hofmann, Rüdiger Hehlmann, and Susanne Saußele. "Older Patients with Chronic Myeloid Leukemia (≥65 Years) Profit More from Higher Imatinib Doses than Younger Patients: A Subanalysis of the Randomized CML-Study IV." Annals of Hematology 93, no. 7 (2014).

MLA (9th ed.) Citation

Proetel, Ulrike, et al. "Older Patients with Chronic Myeloid Leukemia (≥65 Years) Profit More from Higher Imatinib Doses than Younger Patients: A Subanalysis of the Randomized CML-Study IV." Annals of Hematology, vol. 93, no. 7, 2014.